信号序列受体亚单位1在肝细胞癌中的表达及其与预后的关系  

Expression of signal sequence receptor subunit 1 in hepatocellular carcinoma and its relationship with prognosis

作　　者：刘斌 袁倩倩[2] 黄家利 赵甜甜 牛坚 Liu Bin;Yuan Qianqian;Huang Jiali;Zhao Tiantian;Niu Jian(Department of General Surgery,Tengzhou Hospital Affiliated to Xuzhou Medical University,Tengzhou 277500,China;Department of Oncology,Tengzhou Central People's Hospital,Shandong Province,Tengzhou 277500,China;Department of General Surgery,The Affiliated Hospital of Xuzhou Medical University,Xuzhou 221006,China;Department of Pathology,Tengzhou Central People's Hospital,Shandong Province,Tengzhou 277500,China)

机构地区：[1]徐州医科大学附属滕州医院普外科,277500 [2]山东省滕州市中心人民医院肿瘤科,277500 [3]徐州医科大学附属医院普外科,221006 [4]山东省滕州市中心人民医院病理科,277500

出　　处：《中国综合临床》2021年第6期521-525,共5页Clinical Medicine of China

基　　金：江苏省自然科学基金(青年科技人才专项资金)资助项目(BK20161176)。

摘　　要：目的探究信号序列受体亚单位1(signal sequence receptor subunit 1,SSR1)在肝细胞癌中的表达及其与预后的关系。方法检索癌症基因组图谱(The Cancer Genome Atlas,TCGA)数据库至2021年6月20日的肝细胞癌患者SSR1的表达数据及相关的临床资料,并下载相关公开数据。对信息数据完整的334例肝细胞癌组织的SSR1表达水平进行回顾性分析。采用Wilcoxon signed-rank检验分析肝细胞癌与癌旁组织中SSR1基因的表达差异。以SSR1表达水平的中位值(14.660)为界限将肝细胞癌患者分为SSR1高表达组和低表达组。利用χ^(2)检验分析癌组织中SRR1的表达与患者临床病理特征的关系。采用Cox回归和Log-rank生存检验分析肝细胞癌患者的SSR1基因表达、临床病理特征与总生存率的关系,单变量和多变量Cox回归分析确定影响预后的因素。利用基因集富集分析(gene set enrichment analysis,GSEA)方法预测可能相关的调控通路。结果基于TCGA数据库的生物信息学分析表明,SSR1在肝细胞癌组织表达水平(16.320±7.231)明显高于正常肝组织(7.473±1.410),组间比较差异有统计学意义(t=8.621,P<0.001)。SSR1基因高表达组患者的总生存率较低表达组低(χ^(2)=10.1,P=0.001)。SSR1基因的高表达与性别(χ^(2)=4.392,P=0.036)、Stage分期(χ^(2)=6.264,P=0.012)、T分期(χ^(2)=4.561,P=0.033)、Grade分级(χ^(2)=14.015,P<0.001)有关。多因素Cox回归分析结果显示,SSR1基因表达水平升高,肝细胞癌患者死亡风险升高(HR=1.030,95%CI:1.002~1.060,P=0.036),表明SSR1基因是肝细胞癌患者死亡风险预后预测的独立因子。基因集富集分析表明,SSR1高表达与泛素化、细胞周期、RNA降解、MTOR信号通路、WNT信号通路、MAPK信号通路有关。结论SSR1基因在肝细胞癌组织中显著上调,与患者的性别、Stage分期、T分期和Grade分级等有关,是肝细胞癌独立的预后危险因素。泛素化、细胞周期、RNA降解、MTOR信号通路、WNTObjective To explore the expression of signal sequence receptor subunit 1(SSR1)and its prognostic value in hepatocellular carcinoma.Methods Search the expression data and relevant clinical data of SSR1 in hepatocellular carcinoma patients from the Cancer Genome Atlas(TCGA)database to June 20,2021,and download relevant public data.The expression levels of SSR1 in 334 cases of hepatocellular carcinoma with complete information and data were analyzed retrospectively.The expression difference of SSR1 gene between hepatocellular carcinoma and adjacent tissues was analyzed by Wilcoxon signed rank test.Patients with hepatocellular carcinoma were divided into high expression group and low expression group based on the median value of SSR1 expression level(14.660).χ^(2) test was conducted to analyze the relationship between SSR1 expression and clinicopathological features.Cox regression and Log-rank survival test were used to analyze the relationship between SSR1 gene expression,clinicopathological features and overall survival rate in patients with hepatocellular carcinoma.Univariate and multivariate Cox regression analysis were used to determine the factors affecting prognosis.Gene set enrichment analysis(GSEA)was used to predict the possible regulatory pathways.Result Bioinformatics analysis based on TCGA database showed that the expression level of SSR1 in hepatocellular carcinoma(16.320±7.231)was significantly higher than that in normal liver tissue(7.473±1.410).The difference between groups was statistically significant(t=8.621,P<0.001).The overall survival rate of patients with high SSR1 gene expression group was lower than that of patients with high SSR1 gene expression group(χ^(2)=10.1,P<0.001).The high expression of SSR1 gene was related to sex(χ^(2)=4.392,P=0.036),Stage(χ^(2)=6.264,P=0.012),T stage(χ^(2)=4.561,P=0.033)and Grade classification(χ^(2)=14.015,P<0.001).Multivariate Cox regression analysis showed that patients with high expression of SSR1 gene got worse risk of death(HR=1.030,95%CI:1.002-1.06

关 键 词：肝细胞癌 信号序列受体亚单位1 癌症基因组图谱 

分 类 号：R735.7[医药卫生—肿瘤]